Silk Road Medical

What Silk Road Medical does

Silk Road Medical, Inc., founded in 2007 and headquartered in Plymouth, Minnesota, is a medical device company that developed and commercialized the TransCarotid Artery Revascularization (TCAR) procedure for treating carotid artery disease. Its commercial offering is the integrated ENROUTE product family: the ENROUTE Transcarotid Neuroprotection System (NPS Plus), which filters blood flow to capture embolic debris and prevent stroke during the intervention; the ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter for lesion preparation; and the ENROUTE Transcarotid Stent System, a self-expanding stent designed specifically for transcarotid placement. Together these three devices enable a minimally invasive alternative to traditional carotid endarterectomy, addressing a procedure historically performed via open surgical access.

The company monetizes its products through direct sales to U.S. hospitals and vascular surgery centers, supported by clinical specialists and procedural training for vascular surgeons and interventional cardiologists. Pricing is not publicly disclosed, consistent with standard hospital-channel medical-device contracting. Silk Road Medical was publicly traded on NASDAQ under the ticker SILK and grew revenue from approximately $63 million in 2019 to roughly $177 million in 2023, while remaining EBITDA-negative as it invested in commercial scale and adoption of the TCAR procedure. In 2024 the company was acquired by Boston Scientific Corporation for approximately $1.16–1.3 billion and now operates as a private subsidiary within Boston Scientific's vascular product portfolio.

Name

Silk Road Medical

Legal name

Silk Road Medical, Inc.

Website

https://silkroadmed.com

Company type

Private

Founded year

2007

Operating status

Acquired

Headcount range

251–500 employees

Short description

Silk Road Medical develops and sells the ENROUTE ENROUTE integrated device system used in the minimally invasive TCAR procedure to treat carotid artery disease, serving U.S. hospitals and vascular surgeons; the company was acquired by Boston Scientific in 2024.

Ownership category

akta.pro rank

Product category

Vascular Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

akta.pro secondary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Vascular medical devices
• Carotid artery treatment
• Neuroprotection systems
• Endovascular stents
• Minimally invasive surgery

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

Silk Road Medical develops, manufactures, and sells the ENROUTE product family used in TransCarotid Artery Revascularization (TCAR), a minimally invasive procedure for carotid artery disease. The integrated system comprises the ENROUTE Transcarotid Neuroprotection System (NPS Plus) for cerebral embolic protection, the ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter for vessel preparation, and the ENROUTE Transcarotid Stent System for vessel scaffolding. Products are sold directly to hospitals and vascular surgery centers in the United States for use by vascular surgeons and interventional cardiologists.

Product overview

Silk Road Medical is the developer and manufacturer of the TCAR (TransCarotid Artery Revascularization) procedure system, comprising three core products: the ENROUTE Transcarotid Neuroprotection System (NPS Plus) for cerebral protection during procedures, the ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter for lesion preparation and dilation, and the ENROUTE Transcarotid Stent System for vessel scaffolding. These products work together as an integrated system for minimally invasive carotid artery treatment. The company was acquired by Boston Scientific in 2024.

Differentiator

Problem solved

Functional benefit

Brands

• ENROUTE Transcarotid Neuroprotection System: The ENROUTE Transcarotid Neuroprotection System (NPS Plus) is a device used in TCAR procedures for carotid artery disease treatment.
• ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter
• ENROUTE Transcarotid Stent System

Products and services

• ENROUTE Transcarotid Neuroprotection System (NPS Plus) The ENROUTE Transcarotid Neuroprotection System (NPS Plus) is a medical device that provides cerebral protection during TransCarotid Artery Revascularization (TCAR) procedures by filtering blood flow and capturing embolic debris to prevent stroke. It is used by vascular surgeons and interventional cardiologists at hospitals and vascular surgery centers performing minimally invasive carotid artery interventions.
• ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter The ENROUTE Enflate Transcarotid RX (Rapid Exchange) Balloon Dilatation Catheter is a balloon catheter used during TCAR procedures to dilate stenotic lesions in the carotid artery prior to stent placement. Its rapid-exchange design improves trackability and ease of use for vascular surgeons and interventional cardiologists performing TCAR at hospitals and vascular surgery centers.
• ENROUTE Transcarotid Stent System The ENROUTE Transcarotid Stent System is a self-expanding stent designed for implantation in the carotid artery during TCAR procedures. It provides scaffolding to maintain vessel patency following balloon angioplasty of carotid artery stenosis and is intended for use by vascular surgeons and interventional cardiologists at hospitals and vascular surgery centers.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Boston Scientific CorporationcoreOEM/ Whitelabel/ Licensing Partner · 1 September 2024Boston Scientific acquired Silk Road Medical in September 2024 for approximately $1.3 billion, integrating TCAR technology into Boston Scientific's vascular product portfolio. The acquisition provides Boston Scientific access to carotid artery procedure devices and expands its presence in stroke treatment.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Edwards Lifesciences: Edwards Lifesciences is a major cardiovascular device incumbent with strength in heart valves and structural heart, sharing hospital customer relationships and procedural selling infrastructure with Silk Road across the vascular/cardiovascular surgery space.
• Boston Scientific Corporation: Boston Scientific is Silk Road's parent company (acquired 2024) and operates a broad peripheral and coronary vascular intervention portfolio (WATCHMAN, Eluvia, Vici) into which TCAR has been integrated — overlapping on customer base (vascular surgeons and interventionalists) while serving wider indications.

Emerging players

• Penumbra: Penumbra develops neurovascular and peripheral vascular thrombectomy and aspiration devices (e.g., Indigo, Lightning) used in stroke and vascular intervention, overlapping with Silk Road on embolic/emboli protection thinking and on shared vascular specialist customers.
• Terumo Interventional Systems: Terumo manufactures peripheral and coronary interventional devices including guidewires and catheters used in carotid procedures, competing with Silk Road's Enflate balloon catheter in the broader vascular interventional toolkit that supports TCAR and alternative approaches.
• InspireMD: InspireMD is a smaller carotid and neurovascular device company developing next-generation embolic protection and stent systems (CGuard), positioned as a potential emerging alternative to Silk Road's ENROUTE Transcarotid Stent and NPS Plus.
• Contego Medical: Contego Medical develops next-generation embolic protection and carotid intervention devices, with overlapping technology ambitions around integrated neuroprotection and carotid stenting that mirror Silk Road's bundled ENROUTE approach.

Others

• Cardinal Health: Cardinal Health is a large medical product distributor and manufacturer adjacent to vascular intervention devices, an ecosystem participant whose hospital-channel reach and procedural supply relationships support the broader carotid intervention market in which Silk Road competes.

Direct peers

• W. L. Gore & Associates: Gore manufactures the GORE TAG thoracic stent and has participated in carotid intervention through carotid stent and embolic protection offerings, competing with Silk Road in the vascular stent and procedural protection device space serving vascular surgeons.
• Medtronic: Medtronic offers carotid stenting systems and embolic protection devices (e.g., the legacy Mo.Ma Ultra and subsequent iterations) competing with ENROUTE NPS Plus for the same carotid revascularization patient population treated by vascular surgeons and interventional cardiologists.
• Abbott Vascular: Abbott sells carotid artery stents and embolic protection devices (e.g., Acculink/Emboshield via the older Guidant/CES franchise) used in transfemoral carotid stenting — the principal direct alternative to Silk Road's TCAR/ENROUTE approach for treating carotid artery disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/SilkRoadMed
• YouTubeyoutube.com/channel/UC1CMTNd1Zyf7SYg01PJBGEA
• Facebookfacebook.com/SilkRoadMed
• LinkedInlinkedin.com/company/silk-road-med

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Silk Road Medical